NEPHROCARE (NEPHROCARE) fundamentals

NEPHROCARE is a listed company, part of the Healthcare Services sector, listed on the NSE as NEPHROCARE (ISIN INE0SUN01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What NEPHROCARE does

Nephro Care India Limited is an India-based company that operates as a healthcare provider. Its business is to provide a comprehensive 360-degree healthcare service to patients with kidney-related services. It operates only in non-invasive service. It offers a range of clinical and lifestyle solutions and services and renal insufficiency treatment for patients. Its treatment framework covers the entire range of lifestyle, physiological and spiritual aspects of wellness. It provides holistic care for renal failure patients, which includes consultation, treatment, and yoga. It offers nutritional support for diabetic kidney disease, hypertensive nephropathy, glomerular disease, renal transplant recipient, hemodialysis patient, IgA nephropathy, Lupus nephropathy, and ADPKD. It operates various clinics, such as Renal Transplant, Urology, and Vascular Surgery. It also offers other services, such as Pulmonary function test, EMG/NCV-testing, Uroflowmetry, EEG, Polysomnography, and others.

Valuation and market data

Last close₹92.65
Market capitalisation₹142 crore
Enterprise value₹138 crore
P/E (TTM)0.00
Price to book2.65
Price to sales (TTM)0.00
Book value per share₹34.97
Dividend yield0.00%
SectorHealthcare Services
Industry

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹90 crore₹5 crore₹3 crore0.00

Figures are as reported (consolidated), in ₹ crore.

Shareholding pattern

As of Jun 2026:

Promoters61.7%
Foreign institutions (FII)1.0%
Mutual funds0.0%
Other domestic institutions1.3%
Retail and others36.0%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.